

Catalogue
Number

Product

Order number / Unit

99381 PSMA I&T**Precursor for radiometal-labelled PSMA I&T**

PSMA: prostate-specific membrane antigen

Molar Mass: 1498.37 $C_{63}H_{92}IN_{11}O_{23}$

[2192281-54-0] (net peptide)


Colourless to off-white solid packaged in plastic vials

Purity: > 95 %**Certificates:**

CoA; MS (identity); HPLC (purity)

Sequence:

Glu-CO-Lys[(Sub)DLys-DPhe-DTyr(3I)-DOTAGA] trifluoroacetate

Literature:Baum R.P. et al. ^{177}Lu -Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy. *J. Nucl. Med.* 2016, 57, 1006-1013.Eiber M. et al. Systemic Radioligand Therapy with ^{177}Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer. *J. Nucl. Med.*, 2016, 57(supplement 2): p. 61-61.Schottelius M. et al. [^{111}In] PSMA-I&T: expanding the spectrum of PSMA-I&T applications towards SPECT and radioguided surgery. *EJNMMI Res.* 2015, 5, 68.Please inquire for customized
filling and bulk quantities.

date of product catalogue issue: 27 February 2019